相关实验视频

Updated: May 6, 2026

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Measurements of Motor Function and Other Clinical Outcome Parameters in Ambulant Children with Duchenne Muscular Dystrophy

Published on: January 12, 2019

唐氏综合征儿童住院治疗结果:儿童住院数据库研究

Po-Yang Tsou¹, Yu-Hsun Wang², Ignacio E Tapia³

¹Division of Pulmonary Medicine, Boston Children's Hospital, Harvard Medical School, 300 Longwood Avenue, Farley 4, Boston, MA, USA. po-yang.tsou@childrens.harvard.edu.

|August 5, 2025

概括

患有唐氏综合征 (DS) 的黑人儿童在住院期间面临更高的死亡风险和侵入性机械通风 (IMV) 风险. 这些差异凸显出有针对性的干预措施的必要性,以改善这一弱势群体的结果.

科学领域:

儿科健康儿科健康
遗传学和罕见疾病
健康差异在健康上的差异

背景情况:

与一般人群相比,患有唐氏综合征 (DS) 的儿童患多系统并发症和住院病例的比率更高.
在医疗保健获得和结果方面的种族差异是儿科医学的一个重大问题.

研究的目的:

研究唐氏综合征儿童的种族和住院结果之间的关联,包括死亡率.
确定种族差异是否会导致重症监护使用率和停留时间的变化.

主要方法:

从儿童住院患者数据库 (2006-2019) 分析了21岁以下患有DS的儿童的医院出院记录.
主要暴露:黑人种族. 主要结局:侵入性机械通风 (IMV) 和死亡率. 二次结果:非侵入性机械通风 (NIMV),停留时间 (LOS) 和住院费用.
采用多变量后勤回归模型来评估黑人种族与不良结果之间的关系.

主要成果:

这项研究包括163870例住院治疗;其中9.89%是黑人儿童.
患有DS的黑人儿童更有可能更年轻,收入更低,公共保险更高,并承受更高的并发病负担 (例如喘,肥胖,先天性心脏病).
在多变量调整后,黑人种族独立地与增加的死亡率 (OR: 1.35),IMV (OR: 1.34),NIMV (OR: 1.41) 和更长的LOS (IRR: 1.08) 相关.

结论:

住院患有唐氏综合征的黑人儿童具有不同的人口和临床特征,包括更高的并发病率.
患有DS的黑人儿童具有显著增加的死亡风险,需要IMV和长时间住院.
这些发现强调了唐氏综合征儿童医疗保健结果的严重种族差异,需要进一步的研究和有针对性的干预措施.

关键词:

黑色黑色黑色孩子孩子孩子孩子唐氏综合征是什么意思唐氏综合征

更多相关视频

Measuring the Functional Abilities of Children Aged 3-6 Years Old with Observational Methods and Computer Tools

Measuring the Functional Abilities of Children Aged 3-6 Years Old with Observational Methods and Computer Tools

Published on: June 20, 2020

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells

In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells

Published on: March 7, 2025

相关概念视频

Drug Dosing: Infants and Children

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...

Pharmacokinetics in Pediatric Patients: Drug Distribution

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...

Pharmacokinetics in Pediatric Patients: Drug Excretion

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...